A new generation of weight-loss drugs has proven remarkably effective, hugely popular, and massively lucrative in the last few years ...

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find out why NVO stock is a hold.

And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets ...

Side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar ...

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...